Please assess the completion status of the following clinical trial:

Trial Title: Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects will have no history of IOP \> 24 mm Hg in either eye.~* All subjects will have open angles on gonioscopy with the filtering portion of the trabecular meshwork visible for 360° in both eyes.~* Previously or newly diagnosed patient are required to have HVFs that are reliable and show loss consistent with nerve fiber layer atrophy.~* Patients with glaucoma-like discs (CDR\>0.7 in either eye) and normal/reliable visual fields who the PI has opted to observe without treatment will enter the study if they meet the other study criteria.~* In order to facilitate the retinal blood flow measurements, only subjects with refractive error within the range -10 to +10 diopters, no lens opacities greater than 1+ cortical spokes or 2+ nuclear sclerosis, and pupillary dilation of at least 6 mm following mydriasis will be included.~Exclusion Criteria:~* Patients with evidence of exfoliation or pigment dispersion syndrome in either eye.~* Patients with a cup/disc ratio \> 0.8.~* Known history of allergy to brimonidine.~* Patients already on treatment with brimonidine will be excluded from the study.~* Diabetic retinopathy.~* History of ocular laser or incisional surgery in either eye.~* Use of systemic alpha-2 blockers.~* Pregnant or planning to become pregnant.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients with RVD (Type: EXPERIMENTAL): Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).